Hillstream BioPharma (HILS) Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Hillstream BioPharma (HILS) Provides Corporate Update

Hillstream BioPharma Provides Corporate Update

June 2, 2022 8:47 AM EDT

Recent milestones include FDA Orphan Drug Designations for HSB-1216 and HSB-888 World-class scientific advisory team and growing and distinguished patent portfolio remain key competitive advantages Company ended Q1 2022 with $11 million in cash Provides roadmap of clinical plans through 2023

BRIDGEWATER, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (Hillstream, the Company), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death for drug resistant and devastating cancers, today provided a corporate... More